Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
SHEIN Launches SHEIN Exchange Resale Platform in Europe and the United Kingdom
SHEIN Exchange, an integrated online peer-to-peer resale platform to buy and sell previously owned SHEIN products, is launching across three of SHEIN's markets in phases. Users in France can now access the SHEIN Exchange platform, with the resale platform to be made available in the UK and Germany in subsequent phases. SHEIN Exchange, an integrated online peer-to-peer resale platform to buy and sell previously owned SHEIN products, is launching across three of SHEIN's markets in phases...
PR Newswire
03/06/2024
Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by…
Key Takeaways from the Bispecifics/Trispecifics Market Report Key Takeaways from the Bispecifics/Trispecifics Market Report Discover which therapies are expected to grab the major bispecific/trispecific market share @Bispecifics/Trispecifics Market Report Bispecifics/Trispecifics Overview Bispecific antibodies are designed to simultaneously attach to two distinct epitopes or antigens, offering a promising avenue for enhancing target specificity. This dual-binding capability...
PR Newswire
03/06/2024
MuscleBlaze BIOZORB Whey Protein redefines fitness in UAE with Cutting-edge…
MuscleBlaze BIOZORB whey protein range transcends conventional supplements with its U.S. Patent published formulation. This underscores MuscleBlaze's commitment to advancing the boundaries of nutritional science. MuscleBlaze BIOZORB whey protein range transcends conventional supplements with its U.S. Patent published formulation. This underscores MuscleBlaze's commitment to advancing the boundaries of nutritional science. Maximizing Performance: Clinically Tested 50% Enhanced Protein...
PR Newswire
03/06/2024
STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA…
CAMBRIDGE, England, June 3, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that interim Phase 1 clinical data from its first-in-class lead product, STC-15, was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, US. CAMBRIDGE, England,June 3, 2024/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company...
PR Newswire
03/06/2024
Orion is developing the Finnish life science industry in a unique collaboration…
ORION CORPORATIONPRESS RELEASE03 June 2024 at 09.30 EEST Orion is developing the Finnish life science industry in a unique collaboration project Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding. The project seeks to enhance advanced pharmaceutical and life science manufacturing in Finland. The LifeFactFuture project combines world-class-excellence of Finnish life science companies, technology...
Nasdaq GlobeNewswire
03/06/2024
RAMSAY SANTE : Agreement reached with the government on funding of private…
PRESS RELEASEParis, 3 June 2024 Agreement reached with the government on fundingof private hospitals After two months of mass mobilisation and intense discussions with the government, a compromise was reached on 24 May 2024 between the government and the Federation of private clinics and hospitals, set out in a letter of commitment from the delegate Ministry of Health.The Government's commitment includes, first and foremost,the principle of equal treatment between the private...
Nasdaq GlobeNewswire
03/06/2024
Augnito Appoints Hamza Moftah as Associate Vice President of Sales to Accelerate…
Rustom Lawyer, Co-Founder & CEO of Augnito, expressed his enthusiasm for Hamza's appointment, stating, "The GCC region is of paramount importance to us as AI innovators. Hamza's deep understanding of the digital health landscape and his ability to drive impactful change will be instrumental in our mission to empower clinicians, ensure the highest levels of quality and precision in documentation and administration, and improve patient outcomes in the region." Rustom Lawyer…
PR Newswire
03/06/2024
Pharming Group to participate in June investor conferences
Leiden, the Netherlands, June 3, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News”...
Nasdaq GlobeNewswire
03/06/2024
Number of voting rights as of May 31, 2024
Nicox SA Société anonyme with a registered capital of € 502,996.94 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On June 3 rd, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article 223-16 of the General Regulation of the AMF) Market: Euronext Growth ParisISIN Code: FR0013018124 Website:www.nicox.com As of May 31, 2024...
Nasdaq GlobeNewswire
03/06/2024
Ipsen initiates a share buy-back program to cover its free employee…
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share planPARIS, FRANCE, 3 June 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 400,000, or about 0.47% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen's free employee share-allocation...
Nasdaq GlobeNewswire
03/06/2024
New data with daridorexant to be presented at SLEEP 2024
Allschwil, Switzerland – June 3, 2024Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at SLEEP 2024 – the 38 thAnnual Meeting of the Associated Professional Sleep Societies, taking place in Houston, Texas, from June 1– 5, 2024.Posters for daridorexant include the following: Kaufmann P, et al. Excretion of the dual orexin receptor antagonist daridorexant into...
Nasdaq GlobeNewswire
03/06/2024
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
As part of the BLA submission process, Telix has requested a Priority Review under the eligibility criteria of the Breakthrough Therapy designation[6]. If granted, this would potentially support an expedited review time. If Zircaix®[2] is approved, TLX250-CDx will be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer to be commercially available in the U.S. and further builds on Telix's successful urology imaging franchise. As part of the BLA submission…
PR Newswire
03/06/2024
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody®…
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide (R 2 ) experienced a 95% overall response rate (ORR) Results from the optimization cohort of the EPCORE™ NHL- 1 study show that mitigation strategies led to a clinically significant reduction in rate of cytokine release...
Nasdaq GlobeNewswire
02/06/2024
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per…
The HEAD registry, with nearly 800 patients, serves to evaluate the economic and social impact of allergies at a European level VALENCIA, Spain, June02, 2024(GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is holding its congress at the Feria de Valencia until Monday, June 3...
Nasdaq GlobeNewswire
02/06/2024
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
JEDDAH, Saudi Arabia, June02, 2024(GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath the skin, signals not...
Nasdaq GlobeNewswire
02/06/2024
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in…
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in evaluable naïve patients; 68% DCR in evaluable resistant patients as per RECIST 1.1Preliminary review of survival data in ITT...
Nasdaq GlobeNewswire
02/06/2024
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly®…
CHMP recommendation is primarily based on the results of GEMSTONE-302, a multi-center, randomized, double-blind, Phase 3 clinical trial. Sugemalimab in combination with chemotherapy significantly improved PFS and OS compared to placebo in combination with chemotherapy in previously untreated stage IV NSCLC patients. The study results have been published in The Lancet Oncology and Nature Cancer and reported in oral sessions at various international academic conferences. CHMP recommendation is...
PR Newswire
01/06/2024
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with…
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024—...
Nasdaq GlobeNewswire
01/06/2024
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with…
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024Genmab...
Nasdaq GlobeNewswire
01/06/2024
Ultimovacs Announces Poster Presentation at the 2024 American Society of…
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website: https://meetings.asco...
Nasdaq GlobeNewswire
01/06/2024
RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC ("Bidco") which is…
MANHATTAN BEACH, Calif., June 01, 2024 /PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the "Offer Document") in relation to Bidco's offer to acquire the entire issued and to be issued share capital of MariaDB plc (the "Offer") had been published and posted to shareholders of MariaDB plc. MANHATTAN BEACH, Calif.,June 01, 2024/PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the " Offer Document ") in…
PR Newswire
01/06/2024
EAACI Congress Kicks Off in Valencia, Spain
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May31, 2024(GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient care through the power of data science.” Over the next four days, experts will discuss the latest advancements in this impactful area. Allergies, which represent a significant public health issue, encompass a variety of conditions. Drug allergy is a major adverse...
Nasdaq GlobeNewswire
31/05/2024
Groupe Casino: Disposal of 90 stores to Groupement Les Mousquetaires and Auchan…
Disposal of 90 stores to GroupementLes Mousquetaires and Auchan Retail France Paris, 31 May 2024Following the agreements reached on 24 January 2024, with Groupement Les Mousquetaires and Auchan Retail France and as well as on 8 February 2024, with Carrefour to sell a combined total of 287 stores, Casino Group announces today the sale of 90 stores 1. The disposals of the remaining 76 stores will occur on 1 July 2024. This transaction is based on an enterprise value of the stores...
Nasdaq GlobeNewswire
31/05/2024
Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine
If approved, IXCHIQ ®will become the first vaccine available in the EU against the chikungunya virus (CHIKV)Decision on EU marketing authorization expected in the third quarter of 2024 Saint Herblain (France), May 31, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization...
Nasdaq GlobeNewswire
31/05/2024
Altri Comunicati
